Pfizer Inc. $PFE Shares Sold by Forum Financial Management LP

Forum Financial Management LP lowered its stake in Pfizer Inc. (NYSE:PFE) by 23.4% in the second quarter, Holdings Channel.com reports. The institutional investor owned 80,084 shares of the biopharmaceutical company’s stock after selling 24,412 shares during the quarter. Forum Financial Management LP’s holdings in Pfizer were worth $1,941,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of PFE. GKV Capital Management Co. Inc. acquired a new stake in Pfizer during the 1st quarter valued at approximately $27,000. North Capital Inc. acquired a new stake in Pfizer during the 1st quarter valued at approximately $28,000. Bayforest Capital Ltd acquired a new stake in Pfizer during the 1st quarter valued at approximately $28,000. Harbor Asset Planning Inc. acquired a new stake in Pfizer during the 2nd quarter valued at approximately $29,000. Finally, Horizon Financial Services LLC acquired a new stake in Pfizer during the 1st quarter valued at approximately $35,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE opened at $24.72 on Thursday. The firm has a market capitalization of $140.52 billion, a price-to-earnings ratio of 13.15, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a one year low of $20.92 and a one year high of $29.17. The stock’s fifty day moving average is $24.88 and its 200-day moving average is $24.13.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s payout ratio is presently 91.49%.

Analysts Set New Price Targets

A number of brokerages have weighed in on PFE. UBS Group restated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Bank of America increased their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Finally, Citigroup increased their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $28.13.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.